KEYNOTE-689 Results Provide “Foundation” for Alternative HNSCC Strategies

Commentary
Video

Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.

Douglas R. Adkins, MD, professor and medical oncologist in the John T. Milliken Department of Medicine of Washington University in St. Louis, MO, spoke with CancerNetwork® about next steps for researching pembrolizumab (Keytruda)-based treatment in patients with head and neck squamous cell carcinoma (HNSCC). The discussion was contextualized by findings from the phase 3 KEYNOTE-689 (NCT03765918) trialassessing the addition of neoadjuvant and adjuvant pembrolizumab to standard-of-care (SOC) surgery and radiation or chemoradiotherapy in this patient population he presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

Adkins suggested that data from the trial provide a new foundation to develop strategies that can elicit higher cure rates among patients with locally advanced head and neck cancer, given the potential of relapse even with the addition of neoadjuvant and adjuvant pembrolizumab to surgery followed by radiation or chemoradiation. He explained that potential strategies may include adding other therapeutic agents to pembrolizumab to enhance its efficacy.

Another opportunity, he claims, might include an investigation into the relative contribution of pembrolizumab to responses both before and after surgery in this patient population. He concluded by emphasizing the potential to develop new research pathways that expand upon the results uncovered in the investigation of KEYNOTE-689.

Transcript

[The KEYNOTE-689 data] provide a new foundation to work on developing alternative or additional strategies that can further improve the chance of curing patients with locally advanced head and neck cancer. Relapse is still an event that does occur in patients who are treated with pembrolizumab, along with surgery-based treatment. There are opportunities to further reduce the chance of relapse and improve the [cure rates].

These opportunities could include [adding] drugs to pembrolizumab before and after surgery-based treatment––drugs that might enhance the efficacy of pembrolizumab. There are other opportunities to investigate the relative contribution of pembrolizumab given before surgery vs given after surgery. There are rich opportunities to develop new research pathways that build upon the results of the perioperative pembrolizumab approach that was investigated in KEYNOTE-689.

Reference

Adkins D, Haddad RI, Tao Y, et al. Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): exploratory efficacy analyses of the phase 3 KEYNOTE-689 study. J Clin Oncol. 2025;43(suppl 16):6012. doi:10.1200/JCO.2025.43.16_suppl.6012

Recent Videos
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Related Content